Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
India has revoked a patent granted to GlaxoSmithKline Plc for breast cancer drug Tykerb, a decision that follows a landmark India court ruling disallowing patents for incremental innovations that was a blow to global pharmaceutical firms. However, India's Intellectual Property Appellate Board (IPAB) upheld a patent granted on the original compound, or active pharmaceutical ingredient, lapatinib, citing innovative merit. As a result, a GSK spokesman said its medicine would remain subject to patent protection until 2019.
Help employers find you! Check out all the jobs and post your resume.
India has revoked a patent granted to GlaxoSmithKline Plc for breast cancer drug Tykerb, a decision that follows a landmark India court ruling disallowing patents for incremental innovations that was a blow to global pharmaceutical firms. However, India's Intellectual Property Appellate Board (IPAB) upheld a patent granted on the original compound, or active pharmaceutical ingredient, lapatinib, citing innovative merit. As a result, a GSK spokesman said its medicine would remain subject to patent protection until 2019.
Help employers find you! Check out all the jobs and post your resume.
